Sitryx develops disease-modifying therapeutics that target immune cell metabolism to correct dysregulated immune responses in chronic autoimmune and inflammatory diseases. Their pipeline includes first- and best-in-class therapies designed to rebalance the immune system and achieve disease remission, supported by a collaboration with Eli Lilly worth up to $1.1 billion.
Funding
$79.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OSFounders
Product
Problem
Chronic autoimmune and inflammatory diseases are characterized by dysregulated immune responses. Current treatments often fail to address the underlying metabolic dysfunction within immune cells that drives these imbalances. This can lead to inadequate disease control and limited potential for remission.
Solution
Sitryx is developing immunometabolic therapies designed to rebalance the immune system and resolve chronic autoimmune and inflammatory diseases. By targeting intracellular metabolic pathways within immune cells, their approach aims to correct the functional identity of these cells and restore immune homeostasis. Their pipeline includes first- and best-in-class therapeutics that offer a differentiated approach to treating disease by modulating immune cell metabolism. These therapies have the potential to achieve disease remission and improve patient outcomes by addressing the root cause of immune dysfunction.
Target Audience
The primary target audience includes patients suffering from chronic autoimmune and inflammatory diseases, as well as healthcare providers seeking disease-modifying therapeutics with the potential to achieve remission.
Features
- Focus on immunometabolism to correct dysregulated immune responses
- Pipeline of first- and best-in-class therapies
- Modulates the metabolism of immune cells
- Aims to rebalance the immune system and achieve disease remission